Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02414230 · ClinicalTrials.gov registry record

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

A clinical trial, sponsored by Tammie L. S. Benzinger, MD, PhD.

Completed
Registry status
9
Enrollment target

NCT02414230: Completed study, sponsored by Tammie L. S. Benzinger, MD, PhD.

NCT02414230 is a clinical trial that has completed, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02414230 has completed, sponsored by Tammie L. S. Benzinger, MD, PhD.

COMPLETED
Registry status
9 participants
Enrollment target

Study Summary

The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.

Interventions

  • DRUG Drug: F 18 T807

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2015-02
Est. Completion 2020-06-10
Tammie L. S. Benzinger, MD, PhD

8 total trials

What the finished NCT02414230 record still lists

NCT02414230 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Drug: F 18 T807 is the first listed.

NCT02414230 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02414230 about?

NCT02414230 is a clinical study titled "F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis". The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.

What is the current status of trial NCT02414230?

This trial is currently completed. The enrollment target is 9 participants. The study started on 2015-02. Estimated completion is 2020-06-10.

What interventions are being tested in trial NCT02414230?

The interventions under investigation include: Drug: F 18 T807 (DRUG).

Who is sponsoring clinical trial NCT02414230?

This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02414230, the US trial registry maintained by the National Library of Medicine. NCT02414230 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.